The present invention discloses rapid and cost-effective method of de-glycosyation of a glycoprotein, wherein, glycoprotein is combined with anionic surfactant and reducing agent and non-ionic surfactant in order to obtain stable denatured glycoprotein. An endoglycosidase is further added to denatured glycoprotein to cleave N-linked glycans in order to obtain de-glycosylated protein. A rapid tool for assessing the protein conformation by partial de-glycosylation is also presented wherein the partial de-glycosylated protein is analysed using capillary electrophoresis (CE-SDS).

The disclosure is in the technical field of synthetic biology and metabolic engineering. The disclosure provides engineered viable bacteria. In particular, the disclosure provides viable bacteria with mutated outer membrane biosynthetic pathway leading to disruption of the pathway, preferably substantially lacking lipopolysaccharide (LPS, endotoxin) within the outer membrane. The disclosure further provides methods of generating viable bacteria and uses thereof. The disclosure also provides compositions and methods for inducing immune responses and for researching and developing therapeutic agents. Furthermore, the disclosure is in the technical field of fermentation of metabolically engineered microorganisms producing bioproduct or metabolite.

The present disclosure is generally related to the fields of biology, molecular biology, genetics, microbial host cells, industrial enzyme production, and the like. More particularly, certain embodiments of the disclosure are related to microbial host cells for the production of heterologous proteins, which microbial host cells are well-suited for growth in submerged cultures for the large-scale production of heterologous cyanuric acid hydrolases and biuret hydrolases.

The present disclosure is generally related to the fields of biology, molecular biology, genetics, microbial host cells, industrial enzyme production, and the like. More particularly, certain embodiments of the disclosure are related to microbial host cells for the production of heterologous proteins, which microbial host cells are well-suited for growth in submerged cultures for the large-scale production of heterologous cyanuric acid hydrolases and biuret hydrolases.

Certain embodiments provide a method of reducing biuret in a urea composition, the method comprising contacting the urea composition with an isolated or purified biuret hydrolase enzyme under conditions suitable to reduce the concentration of biuret in the urea composition.

Certain embodiments provide a method of reducing biuret in a urea composition, the method comprising contacting the urea composition with an isolated or purified biuret hydrolase enzyme under conditions suitable to reduce the concentration of biuret in the urea composition.

The present disclosure relates to AAV gene therapy vectors, AAV replicons, and pharmaceutical compositions for delivering a human HDAC8 gene to a subject for treating Cornelia de Lange Syndrome. In addition, methods of treatment and gene transfer are provided.

A method of treating or preventing P. acnes and/or S. aureus infection is described, involving contacting P. acnes and/or S. aureus, or a physiological locus infected or susceptible to infection by P. acnes and/or S. aureus, with at least one of specified bacteriolytic agents. Corresponding pharmaceutical compositions containing such bacteriolytic agents are described, which are useful for treatment or prophylaxis of acne vulgaris and/or S. aureus infection, including methicillin-resistant S. aureus infection.

A method of treating or preventing P. acnes and/or S. aureus infection is described, involving contacting P. acnes and/or S. aureus, or a physiological locus infected or susceptible to infection by P. acnes and/or S. aureus, with at least one of specified bacteriolytic agents. Corresponding pharmaceutical compositions containing such bacteriolytic agents are described, which are useful for treatment or prophylaxis of acne vulgaris and/or S. aureus infection, including methicillin-resistant S. aureus infection.

The present disclosure provides compositions with a modulating gene expression and methods for modulating transcription.